Halozyme's Upcoming Investor Conferences: Key Dates and Engagements

Halozyme to Make Waves at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a pioneering biopharmaceutical company, is set to participate in a series of significant investor conferences in September 2026. With a focus on their cutting-edge therapies and innovative drug delivery technologies, Halozyme is gearing up for engaging discussions with investors and stakeholders.

Who Will Attend?

Leading the charge will be Dr. Helen Torley, the President and CEO, alongside Darren Snellgrove, the Chief Financial Officer. Their participation is aimed at showcasing Halozyme's commitment to enhancing patient care through advanced therapeutic solutions.

Conference Details

1. Wells Fargo 21st Annual Healthcare Conference
- Format: Fireside Chat and 1-on-1 Meetings
- Date: Wednesday, September 9, 2026
- Time: 12:45 PM PT / 3:45 PM ET

2. Morgan Stanley 24th Annual Global Healthcare Conference
- Format: Fireside Chat and 1-on-1 Meetings
- Date: Tuesday, September 15, 2026
- Time: 4:45 AM PT / 7:45 AM ET

3. H.C. Wainwright 28th Annual Global Investment Conference
- Format: Fireside Chat and 1-on-1 Meetings
- Date: Wednesday, September 16, 2026
- Time: 7:00 AM PT / 10:00 AM ET

Audio webcasts of these events will be accessible through the Investor Relations section of Halozyme's website, with replays available for a total of 90 days following each conference.

About Halozyme

Founded with the mission of transforming patient experiences, Halozyme is recognized for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20. This innovation allows for the subcutaneous administration of various injected drugs and fluids, significantly minimizing the treatment burden for patients. The technology has positively impacted over one million patients worldwide, with ten commercialized products currently available across more than 100 global markets. Halozyme has also partnered with leading pharmaceutical companies like Roche, Takeda, and Pfizer to enhance therapeutic delivery systems.

Moreover, the company is on the leading edge of expanding its portfolio by integrating Hypercon™ and Surf Bio’s hyperconcentration technologies into their offerings. These innovations aim to optimize drug delivery further, promising a more efficient and patient-friendly experience.

Halozyme continues to innovate with a range of drug-device combination products that utilize advanced auto-injector technologies designed to enhance comfort and reliability for patients. Their proprietary products, such as Hylenex® and XYOSTED®, are instrumental in advancing the standard of care.

Headquartered in San Diego, California, Halozyme also maintains operations in New Jersey, Minnesota, and Massachusetts, showcasing a robust infrastructure dedicated to research and development in biopharmaceuticals.

Conclusion

As Halozyme prepares to engage with the investment community, the spotlight will be on how their pioneering solutions can further revolutionize patient care and treatment protocols. Investors and stakeholders alike will be keenly aware of the advancements that Halozyme is championing in the field of biopharmaceuticals, marking these conferences as pivotal moments of insight and collaboration.

For more information or inquiries, please contact Tram Bui or Sydney Charlton through the provided contacts.